{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T02:54:40Z","timestamp":1772074480693,"version":"3.50.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.diabres.2020.108462","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T13:03:05Z","timestamp":1600693385000},"page":"108462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes"],"prefix":"10.1016","volume":"170","author":[{"given":"Pieter","family":"Gillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2020.108462_b0005","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 9th ed. In. Brussels, Belgium; 2019."},{"issue":"24","key":"10.1016\/j.diabres.2020.108462_b0010","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.diabres.2020.108462_b0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2020.108462_b0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0030","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0035","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"Supplement 1","key":"10.1016\/j.diabres.2020.108462_b0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2337\/db18-213-OR","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes\u2014DEPICT-2 study","volume":"67","author":"Mathieu","year":"2018","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.diabres.2020.108462_b0045","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diab Endocrinol"},{"issue":"24","key":"10.1016\/j.diabres.2020.108462_b0050","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108462_b0055","doi-asserted-by":"crossref","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in Combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2020.108462_b0060","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108462_b0065","unstructured":"First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes [press release]. European Medicines Agency, 01\/02\/2019; EMA\/CHMP\/46542\/2019; 2019."},{"key":"10.1016\/j.diabres.2020.108462_b0070","unstructured":"New add-on treatment to insulin for treatment of certain patients with type 1 diabetes [press release]. European Medicines Agency; 01\/03\/2019."},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/dc17-1118","article-title":"Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset","volume":"41","author":"Costacou","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0080","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2337\/dc18-2062","article-title":"Risk factors for kidney disease in type 1 diabetes","volume":"42","author":"Perkins","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0085","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2215\/CJN.03700417","article-title":"Diabetes and CKD in the United States population, 2009\u20132014","volume":"12","author":"Zelnick","year":"2017","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0090","doi-asserted-by":"crossref","first-page":"218","DOI":"10.23736\/S0026-4806.17.05496-9","article-title":"Diabetic nephropathy in type 1 diabetes","volume":"109","author":"Papadopoulou-Marketou","year":"2018","journal-title":"Minerva Med"},{"issue":"7","key":"10.1016\/j.diabres.2020.108462_b0095","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","article-title":"The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes","volume":"58","author":"Groop","year":"2009","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000074","article-title":"Early diabetic nephropathy in type 1 diabetes: new insights","volume":"21","author":"Bjornstad","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"23","key":"10.1016\/j.diabres.2020.108462_b0105","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41581-018-0001-y","article-title":"CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease","volume":"14","author":"Anders","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0115","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc17-0906","article-title":"Low incidence of end-stage renal disease in childhood-onset type 1 diabetes followed for up to 42 years","volume":"41","author":"Gagnum","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0272-6386(03)00414-1","article-title":"Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry","volume":"42","author":"Nishimura","year":"2003","journal-title":"Am J Kidney Dis: Off J Natl Kidney Found"},{"issue":"2","key":"10.1016\/j.diabres.2020.108462_b0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/dc13-1287","article-title":"Risk for end-stage renal disease over 25 years in the population-based WESDR cohort","volume":"37","author":"Lecaire","year":"2014","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.diabres.2020.108462_b0130","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jama.294.14.1782","article-title":"Incidence of end-stage renal disease in patients with type 1 diabetes","volume":"294","author":"Finne","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc17-2364","article-title":"Incidence of end-stage renal disease in patients with type 1 diabetes","volume":"41","author":"Helve","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2337\/dc18-1276","article-title":"Decreasing cumulative incidence of end-stage renal disease in young patients with type 1 diabetes in Sweden: a 38-year prospective nationwide study","volume":"42","author":"Toppe","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0145","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"11","key":"10.1016\/j.diabres.2020.108462_b0150","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2337\/dc15-0641","article-title":"The presence and consequence of nonalbuminuric chronic kidney disease in patients with type 1 diabetes","volume":"38","author":"Thorn","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0155","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1210\/jc.2017-01922","article-title":"Diabetic microvascular disease: an endocrine society scientific statement","volume":"102","author":"Barrett","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.diabres.2020.108462_b0160","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jfma.2018.02.007","article-title":"Update of pathophysiology and management of diabetic kidney disease","volume":"117","author":"Lin","year":"2018","journal-title":"J Formosan Med Assoc = Taiwan yi zhi"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0165","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2020.108462_b0170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diab.32.2.S64","article-title":"The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy","volume":"32","author":"Mogensen","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2020.108462_b0175","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2337\/db09-1744","article-title":"Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study","volume":"59","author":"M\u00f6llsten","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.kisu.2017.10.003","article-title":"Diagnosis of diabetic kidney disease: state of the art and future perspective","volume":"8","author":"Persson","year":"2018","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0185","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2215\/CJN.14831218","article-title":"Early glomerular hyperfiltration and long-term kidney outcomes in type 1 diabetes: the DCCT\/EDIC experience","volume":"14","author":"Molitch","year":"2019","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"key":"10.1016\/j.diabres.2020.108462_b0190","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose co-transporters: functional properties and pharmaceutical potential","author":"Sano","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0200","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2020.108462_b0205","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfz230","article-title":"Renal physiology of glucose handling and therapeutic implications","volume":"35","author":"Cherney","year":"2020","journal-title":"Nephrol, Dial Transpl: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc"},{"key":"10.1016\/j.diabres.2020.108462_b0210","doi-asserted-by":"crossref","first-page":"837421","DOI":"10.1155\/2014\/837421","article-title":"Hypoxia in diabetic kidneys","volume":"2014","author":"Takiyama","year":"2014","journal-title":"Biomed Res Int."},{"issue":"Suppl 2(S2)","key":"10.1016\/j.diabres.2020.108462_b0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition","volume":"21","author":"Dominguez-Rieg","year":"2019","journal-title":"Diab Obesity Metab"},{"issue":"9888","key":"10.1016\/j.diabres.2020.108462_b0220","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2020.108462_b0225","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1053\/j.ajkd.2010.10.007","article-title":"US renal data system 2010 annual data report","volume":"57","author":"Collins","year":"2011","journal-title":"Am J Kidney Dis: Off J Natl Kidney Found"},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0230","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2337\/dc19-0349","article-title":"Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria","volume":"42","author":"Vistisen","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0235","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.2337\/dci19-0030","article-title":"Progression of diabetic kidney disease in the absence of albuminuria","volume":"42","author":"MacIsaac","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0240","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.diabres.2020.108462_b0245","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1703518","article-title":"ACE inhibitors and statins in adolescents with type 1 diabetes","volume":"377","author":"Marcovecchio","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2020.108462_b0250","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.diabres.2020.108462_b0255","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"10184","key":"10.1016\/j.diabres.2020.108462_b0260","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"26","key":"10.1016\/j.diabres.2020.108462_b0265","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0270","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13300-020-00798-x","article-title":"The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes","volume":"11","author":"Yin","year":"2020","journal-title":"Diab Ther: Res, Treat Educ Diab Related Disord"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0275","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol."},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0280","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1016\/j.diabres.2020.108462_b0285","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0290","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0295","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0300","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/medicina55060273","article-title":"Role of vitamin D status in diabetic patients with renal disease","volume":"55","author":"Gembillo","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0305","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/jpgm.JPGM_598_16","article-title":"Effect of Vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: a randomized, double-blind clinical trial","volume":"64","author":"Liyanage","year":"2018","journal-title":"J Postgrad Med"},{"issue":"2","key":"10.1016\/j.diabres.2020.108462_b0310","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/0886022X.2015.1128250","article-title":"Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease","volume":"38","author":"Tiryaki","year":"2016","journal-title":"Ren Fail"},{"issue":"7","key":"10.1016\/j.diabres.2020.108462_b0315","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1007\/s00125-013-2904-2","article-title":"Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?","volume":"56","author":"Cleland","year":"2013","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0320","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jdiacomp.2016.02.011","article-title":"Estimated insulin sensitivity predicts incident micro- and macrovascular complications in adults with type 1 diabetes over 6 years: the coronary artery calcification in type 1 diabetes study","volume":"30","author":"Bjornstad","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.diabres.2020.108462_b0325","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/pedi.12730","article-title":"Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: data from the international SWEET registry","volume":"19","author":"Maffeis","year":"2018","journal-title":"Pediatric Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0330","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0335","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jpeds.2015.05.046","article-title":"Obesity in youth with type 1 diabetes in Germany, Austria, and the United States","volume":"167","author":"DuBose","year":"2015","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40608-018-0193-5","article-title":"Abdominal obesity in type 1 diabetes associated with gender, cardiovascular risk factors and complications, and difficulties achieving treatment targets: a cross sectional study at a secondary care diabetes clinic","volume":"5","author":"Melin","year":"2018","journal-title":"BMC Obes"},{"issue":"8","key":"10.1016\/j.diabres.2020.108462_b0345","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.2337\/diacare.28.8.2019","article-title":"Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study)","volume":"28","author":"Thorn","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2020.108462_b0350","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabres.2016.06.003","article-title":"Prevalence and comorbidities of double diabetes","volume":"119","author":"Merger","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0355","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2337\/dc06-2053","volume":"30","author":"Pambianco","year":"2007","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0360","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2020.108462_b0365","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0370","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0375","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabres.2020.108462_b0380","unstructured":"Lahtela JT, Edelman S, Jendle J, et al. Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes. In: Paper presented at: 55th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 16\u201320, 2019, Barcelona, Spain; 2019."},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0385","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0390","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/ds17-0018","article-title":"Canagliflozin in type 1 diabetes: a case series of patient outcomes in a diabetes clinic","volume":"32","author":"Roberts","year":"2019","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.diabres.2020.108462_b0395","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.129","article-title":"Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes","author":"Schnell","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0400","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0405","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11892-012-0302-7","article-title":"Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms","volume":"12","author":"Intine","year":"2012","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.diabres.2020.108462_b0410","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol, Dial Transpl: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc"},{"key":"10.1016\/j.diabres.2020.108462_b0415","unstructured":"Edelman S, Jendle J, Dandona P, et al. Effect of Adding Dapagliflozin as an Adjunct to Insulin on Urinary Albumin-to-Creatinine Ratio over 52 Weeks in Adults with Type 1 Diabetes. In. https:\/\/www.asn-online.org\/education\/kidneyweek\/2018\/program-abstract.aspx?controlId=3064879, 23-28 October 2018, San Diego, CA: ASN Kidney Week 2018. Abstract TH-PO1156; 2018."},{"key":"10.1016\/j.diabres.2020.108462_b0420","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13098-020-0516-9","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria","volume":"12","author":"Nakamura","year":"2020","journal-title":"Diabetol Metab Syndrome"},{"key":"10.1016\/j.diabres.2020.108462_b0425","unstructured":"Biester T, Nieswandt A, Biester S, et al. DAPADream: improved postprandial glucose control with dapagliflozin as add-on to full closed loop in type 1 diabetes | https:\/\/www.morressier.com\/article\/dapadream-improved-postprandial-glucose-control-dapagliflozin-addon-full-closed-loop-type-1-diabetes\/59d51845d462b80296ca39ea. Published 2019. Updated 2019\/02\/12\/. Accessed."},{"issue":"11","key":"10.1016\/j.diabres.2020.108462_b0430","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.2337\/db09-0693","article-title":"A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes","volume":"58","author":"Wad\u00e9n","year":"2009","journal-title":"Diabetes"},{"issue":"21","key":"10.1016\/j.diabres.2020.108462_b0435","doi-asserted-by":"crossref","first-page":"e10860","DOI":"10.1097\/MD.0000000000010860","article-title":"Association of various glycemic variability indices and vascular outcomes in type-2 diabetes patients: a retrospective study","volume":"97","author":"Tong","year":"2018","journal-title":"Medicine."},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0440","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11892-018-0979-3","article-title":"Diabetic kidney disease: is there a role for glycemic variability?","volume":"18","author":"Subramanian","year":"2018","journal-title":"Curr Diab Rep"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0445","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0450","doi-asserted-by":"crossref","DOI":"10.1177\/1470320318803009","article-title":"Hyperglycemia activates the renin-angiotensin system and induces epithelial-mesenchymal transition in streptozotocin-induced diabetic kidneys","volume":"19","author":"Chen","year":"2018","journal-title":"J Renin-Angiotensin-Aldosterone Syst: JRAAS"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0455","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0460","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"de Boer","year":"2011","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0465","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0470","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00125-019-4871-8","article-title":"Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus","volume":"62","author":"Kopecky","year":"2019","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.diabres.2020.108462_b0475","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.diabres.2020.108462_b0480","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13098-018-0324-7","article-title":"Serum uric acid and renal function in patients with type 1 diabetes: a nationwide study in Brazil","volume":"10","author":"Pizarro","year":"2018","journal-title":"Diabetol Metab Syndrome"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0485","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.semnephrol.2011.08.011","article-title":"Uric acid as a mediator of diabetic nephropathy","volume":"31","author":"Jalal","year":"2011","journal-title":"Semin Nephrol."},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0490","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.kint.2016.11.025","article-title":"The serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes","volume":"91","author":"Ahola","year":"2017","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.diabres.2020.108462_b0495","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.2337\/dc19-0342","article-title":"Preventing early renal loss in diabetes (PERL) study: a randomized double-blinded trial of allopurinol\u2014rationale, design, and baseline data","volume":"42","author":"Afkarian","year":"2019","journal-title":"Diabetes Care"},{"issue":"26","key":"10.1016\/j.diabres.2020.108462_b0500","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.diabres.2020.108462_b0505","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2020.108462_b0510","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0515","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2337\/dc12-0850","article-title":"Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes","volume":"36","author":"Theilade","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0520","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcjd.2014.10.013","article-title":"Uric acid as a biomarker and a therapeutic target in diabetes","volume":"39","author":"Lytvyn","year":"2015","journal-title":"Can J Diabetes"},{"issue":"17","key":"10.1016\/j.diabres.2020.108462_b0525","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"issue":"Supplement 1","key":"10.1016\/j.diabres.2020.108462_b0530","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2337\/db18-1116-P","article-title":"Dapagliflozin suppresses plasma hepcidin concentrations","volume":"67","author":"Ghanim","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1758-5996-6-17","article-title":"Nitric oxide system and diabetic nephropathy","volume":"6","author":"Dellamea","year":"2014","journal-title":"Diabetol Metab Syndrome"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0540","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2020.108462_b0545","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fendo.2019.00441","article-title":"Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGFbeta1 signaling","volume":"10","author":"Huang","year":"2019","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0550","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00508-018-1434-9","article-title":"Overweight and obesity in type 1 diabetes equal those of the general population","volume":"131","author":"Fellinger","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0555","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.ajkd.2008.03.003","article-title":"Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study","volume":"52","author":"Foster","year":"2008","journal-title":"Am J Kidney Dis: Off J Natl Kidney Found"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0560","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-144-1-200601030-00006","article-title":"Body mass index and risk for end-stage renal disease","volume":"144","author":"Hsu","year":"2006","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.diabres.2020.108462_b0565","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1681\/ASN.2005060638","article-title":"Obesity and risk for chronic renal failure","volume":"17","author":"Ejerblad","year":"2006","journal-title":"J Am Soc Nephrol: JASN"},{"issue":"4","key":"10.1016\/j.diabres.2020.108462_b0570","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol: JASN"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0575","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mcna.2012.10.010","article-title":"Obesity and diabetic kidney disease","volume":"97","author":"Maric-Bilkan","year":"2013","journal-title":"Med Clin North Am."},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0580","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2020.108462_b0585","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/DMSO.S90662","article-title":"SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin","volume":"8","author":"Seufert","year":"2015","journal-title":"Diab, Metab Syndrome Obesity: Targ Ther"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0590","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0595","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.diabres.2020.108462_b0600","first-page":"121","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0605","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","article-title":"Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption","volume":"23","author":"Chagnac","year":"2008","journal-title":"Nephrol, Dial Transpl: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc"},{"issue":"12","key":"10.1016\/j.diabres.2020.108462_b0610","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dme.12805","article-title":"Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis","volume":"32","author":"Petit","year":"2015","journal-title":"Diab Med: J Brit Diab Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2020.108462_b0615","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0620","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7570\/jomes.2019.28.1.18","article-title":"The Effects of hypoglycemic agents on non-alcoholic fatty liver disease: focused on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"28","author":"Jung","year":"2019","journal-title":"J Obes Metab Syndr."},{"issue":"10","key":"10.1016\/j.diabres.2020.108462_b0625","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00125-018-4678-z","article-title":"SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases","volume":"61","author":"Wanner","year":"2018","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.diabres.2020.108462_b0630","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/hepr.13304","article-title":"Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus","volume":"49","author":"Akuta","year":"2019","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.diabres.2020.108462_b0635","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.diabres.2020.108462_b0640","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1\u20133 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diab, Metab Syndrome Obesity: Targ Ther"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2020.108462_b0645","doi-asserted-by":"crossref","DOI":"10.1210\/js.2019-SAT-LB025","article-title":"SAT-LB025 analysis of benefit\/risk in the subgroup of patients with BMI of equal or larger than 27 kg\/m2 in the dapagliflozin DEPICT-1 and -2 trials in type 1 diabetes","volume":"3","author":"Mathieu","year":"2019","journal-title":"J Endocrine Soc"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822720307154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:14:07Z","timestamp":1759173247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822720307154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":129,"alternative-id":["S0168822720307154"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108462","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2020.108462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108462"}}